HUBEI JUMPCAN PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 41.14 CNY | +2.34% |
|
-2.70% | +30.89% |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +30.89% | 5.24B | D+ | ||
| +33.25% | 704B | C+ | ||
| +28.59% | 577B | B | ||
| -3.55% | 348B | C+ | ||
| +18.16% | 327B | B- | ||
| +4.36% | 288B | C+ | ||
| +14.81% | 234B | B+ | ||
| +4.93% | 198B | B- | ||
| -9.78% | 194B | A+ | ||
| -3.69% | 147B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 600566 Stock
- Ratings Hubei Jumpcan Pharmaceutical Co., Ltd.
